Soluble Corn Fiber Supplementation for Asthma

Asthma in Children Clinical Trial

Official title:

Soluble Corn Fiber Supplementation for Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03673618
• Other study ID #: Phoenixchildrens-18-121
• Status: Completed
• Phase: Phase 2
• Start date: September 1, 2019
• Est. completion date: December 31, 2021

Study information

• Verified date: April 2022
• Source: Phoenix Children's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Studies of the importance of the human microbiome have demonstrated that microbial metabolites of fermentation of our dietary products (e.g. dietary fiber) have a multitude of health benefits. The investigators aim to determine whether supplementation of asthmatic children with soluble corn fiber alongside standard of care reduces airway inflammation driven by the gut microbial metabolites acetate, propionate, or butyrate (short chain fatty acids).

Description:

Asthma is a complex inflammatory disease of the airways that is estimated to affect 300 million people worldwide. Incidence of asthma is steadily increasing in Western populations; an additional 100 million asthma diagnoses are anticipated by the year 2025. Asthma is a multifactorial disease affected by genetic and environmental factors. One major and potentially modifiable environmental factor is the Western diet. The Western diet influences the microbiome, which in turn, may influence inflammatory airway diseases via a gut microbiome-airway connection. The investigators hypothesize that prebiotic dietary fiber supplementation leads to increased circulating short chain fatty acid production and improvement in asthma disease activity. The investigators will recruit 20 children, ages 6-17 years old, with asthma from the Severe Asthma Clinic or General Pulmonary Clinic at Phoenix Children's Hospital. Participants will be randomly assigned (1:1) using a random number generator to ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage or placebo (malodextrin in a similar fruit-flavored beverage) as previously described. Participants will be asked to consume the prebiotic soluble corn fiber (or placebo) for 4 weeks alongside their normal diet and normal asthma treatments. Blood will be collected pre- and post-fiber intervention to measure baseline and post-intervention circulating SCFAs. Stool samples and nasal wash will be collected for microbiome and immune analysis pre- and post- fiber consumption. Nasal washes will be collected pre- and post-fiber consumption to measure inflammatory patterns.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of asthma

• Fractional excretion of exhaled nitric oxide (FeNO) > 50 ppb OR a history of environmental allergies

• No emergency department or hospital visits for asthma in the past 3 months

• No systemic corticosteroids in the past 1 month

• Ability to consume a liquid drink of SCF or placebo

• Ability to return for a 4-6 week follow-up visit

• No special or unique diet as determined by PI/CO-Is.

Exclusion Criteria:

• Cystic fibrosis

• Bronchiectasis

• Change in asthma medicines other than short acting bronchodilators planned over the next 4-6 weeks.

Related Conditions & MeSH terms

• Asthma
• Asthma in Children

Intervention

Drug:
• Soluble Corn Fiber
Fiber or placebo

Locations

Country	Name	City	State
United States	Phoenix Childrens Hospital	Phoenix	Arizona

Sponsors (4)

Lead Sponsor	Collaborator
Phoenix Children's Hospital	Flinn Foundation, Mayo Clinic, Northern Arizona University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Asthma symptoms	Asthma Control Questionnaire	4 weeks
Secondary	Change in Serum Short Chain Fatty Acids		Before treatment period and after treatment for 4 weeks
Secondary	Change in nasal wash Th2 gene expression		Before treatment period and after treatment for 4 weeks
Secondary	Alpha and beta diversity in participants' nasal microbiome		Before treatment period and after treatment for 4 weeks
Secondary	Alpha and beta diversity in participants' stool microbiome		Before treatment period and after treatment for 4 weeks